Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Identification of and human serum reactogenicity to neutralizing epitopes within the central unglycosylated region of the respiratory syncytial virus attachment protein.

Murata Y, Lightfoote PM, Falsey AR, Walsh EE.

Clin Vaccine Immunol. 2010 Apr;17(4):695-7. doi: 10.1128/CVI.00432-09. Epub 2010 Feb 17.

2.

Humoral response to the central unglycosylated region of the respiratory syncytial virus attachment protein.

Murata Y, Lightfoote PM, Biear JN, Falsey AR, Walsh EE.

Vaccine. 2010 Aug 31;28(38):6242-6. doi: 10.1016/j.vaccine.2010.07.011. Epub 2010 Jul 23.

3.

Identification of multiple protective epitopes (protectopes) in the central conserved domain of a prototype human respiratory syncytial virus G protein.

Plotnicky-Gilquin H, Goetsch L, Huss T, Champion T, Beck A, Haeuw JF, Nguyen TN, Bonnefoy JY, Corvaïa N, Power UF.

J Virol. 1999 Jul;73(7):5637-45.

4.

Antibody response to the central unglycosylated region of the respiratory syncytial virus attachment protein in mice.

Murata Y, Catherman SC.

Vaccine. 2012 Aug 3;30(36):5382-8. doi: 10.1016/j.vaccine.2012.06.016. Epub 2012 Jun 19.

5.

The first human epitope map of the alphaviral E1 and E2 proteins reveals a new E2 epitope with significant virus neutralizing activity.

Hunt AR, Frederickson S, Maruyama T, Roehrig JT, Blair CD.

PLoS Negl Trop Dis. 2010 Jul 13;4(7):e739. doi: 10.1371/journal.pntd.0000739.

6.

Role of neutralizing antibodies in adults with community-acquired pneumonia by respiratory syncytial virus.

Luchsinger V, Piedra PA, Ruiz M, Zunino E, Martínez MA, Machado C, Fasce R, Ulloa MT, Fink MC, Lara P, Avendaño LF.

Clin Infect Dis. 2012 Apr;54(7):905-12. doi: 10.1093/cid/cir955. Epub 2012 Jan 11.

7.
8.

[Plasmid construction, expression, immunogenicity and protective efficacy of recombinant protein candidate vaccine of respiratory syncytial virus].

Zeng RH, Gong W, Fang XP, Zhang ZY, Mei XG.

Sheng Wu Gong Cheng Xue Bao. 2005 Jul;21(4):534-9. Chinese.

PMID:
16176088
9.
11.

Antibody-dependent enhancement of respiratory syncytial virus infection by sera from young infants.

Osiowy C, Horne D, Anderson R.

Clin Diagn Lab Immunol. 1994 Nov;1(6):670-7.

12.

Group- and genotype-specific neutralizing antibody responses against respiratory syncytial virus in infants and young children with severe pneumonia.

Sande CJ, Mutunga MN, Medley GF, Cane PA, Nokes DJ.

J Infect Dis. 2013 Feb 1;207(3):489-92. doi: 10.1093/infdis/jis700. Epub 2012 Nov 21.

15.

Kinetics of the neutralizing antibody response to respiratory syncytial virus infections in a birth cohort.

Sande CJ, Mutunga MN, Okiro EA, Medley GF, Cane PA, Nokes DJ.

J Med Virol. 2013 Nov;85(11):2020-5. doi: 10.1002/jmv.23696.

16.
17.
18.

Prevalence of antibodies against HEp-2 cell antigen in infants and children hospitalized with respiratory syncytial virus infection.

Forster J, Maier O, Löbbert J, Kaufmehl K, Streckert HJ, Werchau H.

Infection. 1996 Nov-Dec;24(6):407-11.

PMID:
9007586
19.

Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults.

Gonzalez IM, Karron RA, Eichelberger M, Walsh EE, Delagarza VW, Bennett R, Chanock RM, Murphy BR, Clements-Mann ML, Falsey AR.

Vaccine. 2000 Mar 6;18(17):1763-72.

PMID:
10699324
20.

The immune response of small children by antibodies of different classes to respiratory syncytial virus (RSV) proteins.

Wilczyński J, Lukasik B, Torbicka E, Tranda I, Brzozowska-Binda A.

Acta Microbiol Pol. 1994;43(3-4):369-79.

PMID:
7740987
Items per page

Supplemental Content

Write to the Help Desk